BioLineRx’s (BLRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of BioLineRx (NASDAQ:BLRX) in a report published on Wednesday morning, Benzinga reports. They currently have a $21.00 target price on the biotechnology company’s stock.

Separately, StockNews.com started coverage on BioLineRx in a research note on Thursday, October 31st. They set a “hold” rating on the stock.

BioLineRx Stock Performance

Shares of NASDAQ:BLRX opened at $0.45 on Wednesday. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49. The business’s 50 day moving average price is $0.54 and its 200-day moving average price is $0.63. The firm has a market capitalization of $36.21 million, a PE ratio of -1.01 and a beta of 1.48. BioLineRx has a 1 year low of $0.39 and a 1 year high of $1.93.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $5.39 million for the quarter, compared to analyst estimates of $3.93 million. As a group, equities research analysts expect that BioLineRx will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioLineRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. PVG Asset Management Corp purchased a new stake in BioLineRx in the second quarter valued at $70,000. Atria Investments Inc raised its position in BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares during the period. Finally, CVI Holdings LLC purchased a new stake in BioLineRx in the second quarter valued at $462,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.